中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

73 records (took 0.019 seconds)

    NANOFORMULATION OF VITAMIN D DERIVATIVES AND/OR VITAMIN D METABOLITES
    21.
    发明申请
    NANOFORMULATION OF VITAMIN D DERIVATIVES AND/OR VITAMIN D METABOLITES 有权
    维生素D衍生物和/或维生素D代谢物的纳米制剂

    公开(公告)号：US20130149385A1

    公开(公告)日：2013-06-13

    申请号：US13706755

    申请日：2012-12-06

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/51

    CPC classification number: A61K9/5161 ,  A61K47/48038 ,  A61K47/4823 ,  A61K47/542 ,  A61K47/61 ,  B82Y5/00 ,  Y10S977/773 ,  Y10S977/906

    Abstract: A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight.

    Abstract translation: 包括负载纳米粒子的纳米制剂。 每个纳米颗粒包括包封至少一种维生素D衍生物，至少一种维生素D代谢物或其组合的改性壳聚糖聚合物。 改性的壳聚糖聚合物包括共价连接到选自脂肪酸（ω-3-脂肪酸），氨基酸，脱氧胆酸，藻酸盐，精氨酸 - 藻酸盐，透明质酸，胶原，胶原 - 羟基磷灰石 ，聚（乳酸 - 共 - 乙醇酸）（PLGA）及其组合。 一种结构包括介质和纳米制剂，其中纳米颗粒分散在介质中。 使用纳米制剂治疗病症并改善当前治疗方法的功效的方法，其中患者的耐药性发展包括向患者施用治疗有效量的用于治疗病症的纳米制剂。 包含化妆品的纳米化妆品制剂包括纳米制剂，其中所述改性的壳聚糖聚合物包封所述至少一种维生素D衍生物，并且其中所述至少一种维生素D衍生物包含纳米化妆品制剂的总重量的0.1至20.0重量％ 。

    Method and system with contact lens product for treating and preventing adverse eye conditions
    22.
    发明授权
    Method and system with contact lens product for treating and preventing adverse eye conditions 有权
    用于治疗和预防不良眼睛状况的隐形眼镜产品的方法和系统

    公开(公告)号：US08440217B1

    公开(公告)日：2013-05-14

    申请号：US11153598

    申请日：2005-06-15

    Applicant: Mawaheb M. El-Naggar ,  Shaker A. Mousa

    Inventor： Mawaheb M. El-Naggar ,  Shaker A. Mousa

    IPC: A61F9/00 ,  A61F2/14 ,  B29D11/02 ,  G02B1/04

    CPC classification number: A61F9/0017 ,  B29D11/00096 ,  G02B1/043 ,  C08L83/04 ,  C08L101/14

    Abstract: A contact lens product, a method and system for forming the contact lens product, and a method of using the contact lens product. The contact lens product includes a soft disposable contact lens loaded with a drug and the carriers which carry the drug. The lens has a mechanical and optical structure formed by the core polymer included within the lens. The contact lens product is configured to have the drug released from its carrier continuously into an eye of a mammal while the contact lens product is adhered to the eye of the mammal during a continuous period of time, the drug being configured to treat or prevent at least one adverse condition of the eye of the mammal during the continuous period of time. The mammal may be a human being or a veterinary animal.

    Abstract translation: 隐形眼镜产品，用于形成隐形眼镜产品的方法和系统以及使用隐形眼镜产品的方法。 隐形眼镜产品包括装有药物的软的一次性隐形眼镜和携带药物的载体。 透镜具有由包含在透镜内的芯聚合物形成的机械和光学结构。 隐形眼镜产品被配置为使药物从其载体中连续地释放到哺乳动物的眼睛中，同时将隐形眼镜产品在连续的时间期间附着于哺乳动物的眼睛，该药物被配置为治疗或预防 持续时间内哺乳动物眼睛的至少一种不良状况。 哺乳动物可以是人类或兽医动物。

    OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS
    23.
    发明申请
    OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS 有权
    氧化HEPARIN分子及其在抑制血管生成中的应用

    公开(公告)号：US20110200673A1

    公开(公告)日：2011-08-18

    申请号：US13029584

    申请日：2011-02-17

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/14 ,  A61P7/02 ,  A61K31/727 ,  C08B37/10 ,  A61P35/00 ,  A61K9/00

    CPC classification number: A61K31/727 ,  A61K31/737 ,  A61K45/06 ,  C08B37/0078 ,  A61K2300/00

    Abstract: The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.

    Abstract translation: 本发明涉及包含分子量为约2,000至约4,000道尔顿的成分的肝素级分，其中约1％至约100％的组分的羟基残基被氧化。 本发明还涉及通过施用包含分子量为约2,000至约30,000道尔顿的组分的肝素级分，其中约1％至约100％的羟基，通过施用抑制血管发生并治疗受试者血管生成介导的病症的方法 组分的残基被氧化。 本发明的另一方面涉及包含本发明的肝素级分的组合物。

    Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis
    30.
    发明授权
    Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis 有权
    硫酸化非抗凝血小分子肝素在癌症和肿瘤转移中的组成和方法

    公开(公告)号：US09572831B2

    公开(公告)日：2017-02-21

    申请号：US14526660

    申请日：2014-10-29

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K31/704 ,  A61K31/727 ,  A61K47/48 ,  A61K31/7068 ,  A61K33/24

    CPC classification number: A61K31/727 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K47/6935 ,  A61K47/6937

    Abstract: A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer.

    Abstract translation: 包括纳米颗粒的纳米制剂。 每个纳米颗粒包括壳聚糖，其中糖胺聚糖（GAG被封装），GAG离子或共价键合到壳上，GAG选自硫酸化非抗凝血剂肝素（SNACH），超硫酸化非抗凝血剂肝素 （S-SNACH）及其组合，壳包括聚（乳酸 - 共 - 乙醇酸）（PLGA），聚乙二醇（PEG）-PLGA，马来酰亚胺-PEG-PLGA，壳聚糖，壳聚糖-PLGA，甲氧基 - 聚乙二醇 - 聚（丙交酯 - 共 - 乙交酯）（MPEG-PLGA） - （马来酰亚胺-PEG-PLGA），PLGA-聚己内酯或藻酸钙。使用纳米制剂治疗受试者的癌症的方法包括向患者施用 治疗有效量的用于治疗癌症的纳米制剂。

Patent Agency Ranking